Tarsus Pharmaceuticals (TARS) Long-Term Investments (2022 - 2026)

Tarsus Pharmaceuticals' Long-Term Investments history runs 5 years deep, the most recent figure standing at $3.9 million for Q1 2026.

• In Q1 2026, Long-Term Investments rose 29.0% year-over-year to $3.9 million; the TTM figure through Mar 2026 stood at $3.9 million (up 29.0% YoY), while the FY2025 annual figure was $3.9 million, up 29.0% from the prior year.
• Long-Term Investments for Q1 2026 stood at $3.9 million, roughly flat from $3.9 million in the prior quarter.
• The five-year high for Long-Term Investments was $3.9 million in Q4 2025, with the low at $157000.0 in Q3 2022.
• The 5-year median for Long-Term Investments is $3.0 million (2024), against an average of $1.9 million.
• The sharpest annual moves came in 2024 and 2025: Long-Term Investments surged 1328.57% in 2024, then changed 0.0% in 2025.
• Tarsus Pharmaceuticals' Long-Term Investments stood at $371000.0 in 2022, then surged by 70.08% to $631000.0 in 2023, then jumped by 375.44% to $3.0 million in 2024, then grew by 29.0% to $3.9 million in 2025, then changed by 0.0% to $3.9 million in 2026.
• Business Quant data shows TARS's Long-Term Investments at $3.9 million in Q1 2026, $3.9 million in Q4 2025, and $3.0 million in Q3 2025.